Roger Jeffs Sells 25,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $42.09, for a total transaction of $1,052,250.00. Following the completion of the transaction, the chief executive officer owned 1,348,095 shares of the company’s stock, valued at $56,741,318.55. This trade represents a 1.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total transaction of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total transaction of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total transaction of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total transaction of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total transaction of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total transaction of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total transaction of $1,003,000.00.

Liquidia Trading Up 0.3%

Shares of LQDA stock opened at $42.40 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01. The stock has a market capitalization of $3.77 billion, a P/E ratio of -51.08 and a beta of 0.41. The company has a 50 day moving average price of $36.96 and a 200 day moving average price of $34.71. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $46.67.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $92.02 million during the quarter, compared to analysts’ expectations of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The company’s revenue for the quarter was up 3072.4% compared to the same quarter last year. Equities research analysts predict that Liquidia Corporation will post 1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Farallon Capital Management LLC lifted its position in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in Liquidia during the 3rd quarter worth $38,887,000. Caprock Group LLC acquired a new stake in Liquidia during the 3rd quarter worth $37,114,000. MPM Bioimpact LLC raised its stake in Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after acquiring an additional 1,200,869 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in Liquidia in the third quarter valued at $12,571,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

LQDA has been the subject of several analyst reports. Jefferies Financial Group boosted their price target on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, January 13th. Oppenheimer boosted their price target on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a report on Thursday, March 12th. BTIG Research boosted their price target on shares of Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Wells Fargo & Company boosted their price target on shares of Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Monday, March 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $43.44.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).